Indicator Amino Acid Oxidation in ICU Patients

Critical Illness Clinical Trial

— IAAO-IC  

Official title:

The Effect of Standard or Higher Protein Feeding on Indicator Amino Acid Oxidation in ICU Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06104527
• Other study ID #: NL84098.000.23
• Status: Recruiting
• Phase: N/A
• Start date: October 30, 2023
• Est. completion date: June 2024

Study information

• Verified date: November 2023
• Source: Maastricht University Medical Center
• Contact: Julia Bels, M.D.
• Phone: +316 30 48 06 85
• Email: julia.bels[@]mumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will use the indicator amino acid oxidation technique (IAAO) to determine protein oxidation of ICU patients at two protein intakes: 1.3 g/kg/d versus 2.0 g/kg/d.

Description:

Rationale: While protein administration guidelines for critical care are available from international organizations such as ASPEN and ESPEN, they vary greatly in their recommended dose and are based on relatively low-quality evidence. The Indicator Amino Acid Oxidation (IAAO) technique has been developed as a more practical and non-invasive tool to assess protein metabolism that can be used in vulnerable populations. Application of the IAAO technique in patients admitted to the Intensive Care Unit (ICU) could provide an alternative to better investigate optimal protein feeding during critical illness. Objective: To assess the effect of enteral feeding with higher protein content compared to standard protein content on indicator amino acid oxidation in ICU patients. Study design: Randomized, counterbalanced, cross-over trial. Study population: Adult patients with an unplanned admission to the ICU, who are mechanically ventilated and have an indication for prolonged enteral nutrition. Intervention: Subjects will undergo two test days in randomized order during which they receive either enteral feeding according to a standard protein dose (1.3 g/kg/d) or a higher protein dose (2.0 g/kg/d). Continuous feeding of L-[1-13C]-phenylalanine combined with breath, urine and blood samples will be applied to assess indicator amino acid oxidation. Main study parameters/endpoints: The primary endpoint is indicator amino acid oxidation after enteral feeding with a standard or higher protein content, determined using the Indicator Amino Acid Oxidation (IAAO) method by measuring 13CO2 enrichment in expired breath and enrichment of L-[1-13C]-phenylalanine in plasma and urine. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The overall risk of the study is negligible. The current study compares the effect of two nutritional compositions, that fall within the recommendations of international guidelines on ICU nutrition, on protein metabolism following ICU admission. To avoid overfeeding in the early phase of critical illness, both in terms of calories and protein, full enteral nutrition is provided after three days of gradual increase of intake (i.e., 25-50-75% of targeted intake, on days 1-2-3 respectively). Sampling of breath, urine, feces and plasma does not bring additional risks for this population. Our department has an extensive background in amino acid stable isotope methodology, assessment of 13CO2 enrichment in expired breath samples, and assessment of carbon dioxide production by indirect calorimetry.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years old
• Unplanned admission to the ICU
• Mechanically ventilated
• Start of enteral nutrition within 2 days of intubation
• = 3 days on enteral nutrition
• Expected remaining ICU stay on mechanical ventilation of = 2 days

Exclusion Criteria:

• Contra-indication for enteral nutrition at the discretion of the treating physician
• Feeding intolerance during incremental feeding protocol
• Moribund or withholding of treatment
• On extracorporeal membrane oxygenation (ECMO)
• Presence of chest drains, pneumothorax, tracheoesophageal fistula or subcutaneous emphysema
• Kidney failure AND a "no dialysis"-code on admission
• Hepatic encephalopathy (West Haven criteria 3-4)
• BMI < 18 kg/m2

Related Conditions & MeSH terms

• Critical Illness
• Muscle Wasting
• Muscular Atrophy

Intervention

Combination Product:
• Standard protein enteral nutrition with enteral tracer
Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-[1-13C]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
• High protein enteral nutrition with enteral tracer
Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-[1-13C]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Center+	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Indicator amino acid oxidation	Indicator amino acid oxidation expressed as µmol/kg/h	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission.
Secondary	13CO2 excretion in breath (F13CO2)	Collected using breath samples; measured using gas chromatography-mass spectrometry (Agilent G1530N/G2589A, Little Falls, USA)	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected before start of tracer and at end of tracer protocol.
Secondary	Enrichments of plasma L-[1-13C]-phenylalanine	Collected via in situ arterial catheter; measured using gas chromatography-mass spectrometry (Agilent G1530N/G2589A, Little Falls, USA)	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected before start of tracer and at end of tracer protocol.
Secondary	Enrichments of urine L-[1-13C]-phenylalanine	Collected via indwelling urinary catheter; measured using gas chromatography-mass spectrometry (Agilent G1530N/G2589A, Little Falls, USA)	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected before start of tracer and at end of tracer protocol.
Secondary	Concentration of plasma phenylalanine	Collected via in situ arterial catheter; analyzed using high performance liquid chromatography	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected before start of tracer and at end of tracer protocol.
Secondary	Fecal output and fecal protein content	Collected via in situ fecal collection bag; protein content in fecal samples will be measured using Dumas method (Variomax CN-analyser)	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected from start of intervention until end of intervention & tracer protocol.
Secondary	Enrichment of breath 13CO2	Collected using breath samples; measured using gas chromatography-mass spectrometry (Agilent G1530N/G2589A, Little Falls, USA)	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected before start of tracer and at end of tracer protocol.
Secondary	CO2 production	Measured using indirect calorimetry	Collected at standard vs higher protein administration, on test day 1 and 2 (depending on randomisation order), during the first week of ICU admission. Per test day: collected 2 hours after start of tracer protocol.